中华麻醉学杂志
中華痳醉學雜誌
중화마취학잡지
CHINESE JOURNAL OF ANESTHESIOLOGY
2008年
6期
490-493
,共4页
曾媛%吴新民%朱姜华%杜敏逸
曾媛%吳新民%硃薑華%杜敏逸
증원%오신민%주강화%두민일
羟乙基淀粉%药代动力学%输注,静脉内
羥乙基澱粉%藥代動力學%輸註,靜脈內
간을기정분%약대동역학%수주,정맥내
Hetsstarch%Pharmacokinetics%Infusions,intravenous
目的 比较患者静脉输注6%羟乙基淀粉(HES)130/0.4和HES 200/0.5的药代动力学.方法 择期手术患者20例,ASA Ⅰ级,随机分为2组,HES 130/0.4组和HES 20010.5组,每组10例.分别在30min内静脉输注500 ml HES 130/0.4或HES 200/0.5,蒽酮比色法测定输注后各时点血清中胶体浓度,采用3P97软件计算其药代动力学参数.结果 二室模型权重为1时计算药代动力学参数最符合HES 130/0.4和HES 200/0.5的体内特点,HES 130/0.4主要的药代动力学参数如下:t1/2α=1.7 h、t1/2β=10 h、K10:0.13 h-1、K12=0.133 h-1、K21=0.210 h-1、CL(s)=10.77 L/h、AUC=46 mg·h·ml-1.HES200/0.5主要药代动力学参数如下:t1/2α=3.2 h、t1/2β=164 h、K10=0.09 h-1、K12=0.120 h-1、K21=0.010h-1、CL(s)=0.19 L/h、AUC=53 mg·h·ml-1.结论 HIES 130/0.4和HES 200/0.5在血管内停留时间均较长,HES 130/0.4较HES 200/0.5具有更好的药代动力学特点,其消除半衰期短、在血液内无蓄积.
目的 比較患者靜脈輸註6%羥乙基澱粉(HES)130/0.4和HES 200/0.5的藥代動力學.方法 擇期手術患者20例,ASA Ⅰ級,隨機分為2組,HES 130/0.4組和HES 20010.5組,每組10例.分彆在30min內靜脈輸註500 ml HES 130/0.4或HES 200/0.5,蒽酮比色法測定輸註後各時點血清中膠體濃度,採用3P97軟件計算其藥代動力學參數.結果 二室模型權重為1時計算藥代動力學參數最符閤HES 130/0.4和HES 200/0.5的體內特點,HES 130/0.4主要的藥代動力學參數如下:t1/2α=1.7 h、t1/2β=10 h、K10:0.13 h-1、K12=0.133 h-1、K21=0.210 h-1、CL(s)=10.77 L/h、AUC=46 mg·h·ml-1.HES200/0.5主要藥代動力學參數如下:t1/2α=3.2 h、t1/2β=164 h、K10=0.09 h-1、K12=0.120 h-1、K21=0.010h-1、CL(s)=0.19 L/h、AUC=53 mg·h·ml-1.結論 HIES 130/0.4和HES 200/0.5在血管內停留時間均較長,HES 130/0.4較HES 200/0.5具有更好的藥代動力學特點,其消除半衰期短、在血液內無蓄積.
목적 비교환자정맥수주6%간을기정분(HES)130/0.4화HES 200/0.5적약대동역학.방법 택기수술환자20례,ASA Ⅰ급,수궤분위2조,HES 130/0.4조화HES 20010.5조,매조10례.분별재30min내정맥수주500 ml HES 130/0.4혹HES 200/0.5,은동비색법측정수주후각시점혈청중효체농도,채용3P97연건계산기약대동역학삼수.결과 이실모형권중위1시계산약대동역학삼수최부합HES 130/0.4화HES 200/0.5적체내특점,HES 130/0.4주요적약대동역학삼수여하:t1/2α=1.7 h、t1/2β=10 h、K10:0.13 h-1、K12=0.133 h-1、K21=0.210 h-1、CL(s)=10.77 L/h、AUC=46 mg·h·ml-1.HES200/0.5주요약대동역학삼수여하:t1/2α=3.2 h、t1/2β=164 h、K10=0.09 h-1、K12=0.120 h-1、K21=0.010h-1、CL(s)=0.19 L/h、AUC=53 mg·h·ml-1.결론 HIES 130/0.4화HES 200/0.5재혈관내정류시간균교장,HES 130/0.4교HES 200/0.5구유경호적약대동역학특점,기소제반쇠기단、재혈액내무축적.
Objective To investigate the phannacokinetics of 6% hydroxyethyl starch (lIES) 130/0.4 and 6% HES 200/0.5 after single-dose infusion in healthy patients. Methods Twenty ASA Ⅰ adult patients undergoing elective surgery were randomly divided into 2 groups'( n = 10 each) : group Ⅰ HES 13010.4 and group Ⅱ HES 20010.5. 6% HES 13010.4 and 6% HES 20010.5 500 ml were infused iv over 30 min in group Ⅰ and Ⅱ respectively. Blood samples were taken immediatey before and after HES infusion and at 0.5, 1, 2, 4, 6, 8, 12, 24 and 48 h after HES infusion for determination of serum colloid concentration by anthrone chromatometry. The pharmacokinetie parameters were calculated using software 3P97. Results When weight is 1, the blood colloid concentration vs time curve for HES 130/0.4 and HES 200/0.5 was fitted to a two-compartment model. The main pharmacokinetic parameters for HES 130/0.4:t1/2α = 1.7 h, t1/2β = 10 h, K10 =0.13 h-1 , K12 =0.133 h-1, K21=0.210 h-1, CL(s) = 10.77 L/h, AUC = 46 mg·h·ml-1 . The main pharmacokinetic parameters for HES 200/0.5:t1/2α = 3.2 h, t1/2β= 164 h, K10 = 0.09 h-1 , K12 = 0.120 h-1 ,K21 = 0.010 h-1 , CL(s) = 0.19 L/h, AUC = 53 mg·h·ml-1. Conclusion Both HES 130/0.4 and HES 20010.5 stay in the circulation fairly long. The pharmacokinetic profile of HES 130/0.4 is better than that of HES 200/0.5 after single-dose administration in terms of elimination half time and accumulation in blood. The elimination half time is shorter and there is no intravascular accumulation.
